ClinVar Miner

Submissions for variant NM_003119.4(SPG7):c.1053dup (p.Gly352fs)

dbSNP: rs760818649
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000461092 SCV000552953 pathogenic Hereditary spastic paraplegia 7 2024-01-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gly352Argfs*44) in the SPG7 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG7 are known to be pathogenic (PMID: 21623769, 22964162). This variant is present in population databases (rs760818649, gnomAD 0.04%). This premature translational stop signal has been observed in individuals with hereditary spastic paraplegia (HSP) (PMID: 18563470, 21623769, 23065789, 23733235, 24727571, 25681447). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 411675). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000824802 SCV000731818 pathogenic Hereditary spastic paraplegia 2017-08-02 criteria provided, single submitter clinical testing The p.Gly352ArgfsX44 (NM_003119.2 c.1053dup) (also referred to as c.1053_1054ins C or c.1047insC in the literature) variant in SPG7 has been reported in 7 compou nd heterozygous and 2 homozygous individuals with clinical diagnosis of heredita ry spastic paraplegia or ataxia, and segregated in two affected homozygous sibli ngs in one family (Tzoulis 2008, Klebe 2012, van Gassen 2012, Yoon 2013, Pfeffer 2015, Rydning 2016). This variant has also been reported in ClinVar (Variation ID#411675) as pathogenic by one laboratory. It has been identified in 23/125,780 European chromosomes by the Genome Aggregation Database (http://gnomad.broadins titute.org; rs760818649). This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at position 352 and leads to a premature termination codon 44 amino acids downstream. This alteration is the n predicted to lead to a truncated or absent protein. Biallelic loss of function of the SPG7 gene has been associated with hereditary spastic paraplegia. In sum mary, the p.Gly352ArgfsX44 variant meets criteria to be classified as pathogenic for hereditary spastic paraplegia in an autosomal recessive manner based on its biallelic occurrence in individuals with this disease and its predicted null ef fect.
GeneDx RCV000627428 SCV000748426 pathogenic not provided 2023-06-22 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 32816195, 34758253, 27957547, 23733235, 25681447, 28444220, 30609409, 31589614, 18563470, 25976027)
Eurofins Ntd Llc (ga) RCV000627428 SCV000859029 pathogenic not provided 2018-01-02 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000627428 SCV001476953 pathogenic not provided 2022-07-05 criteria provided, single submitter clinical testing This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features associated with this gene. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic.
Centogene AG - the Rare Disease Company RCV000461092 SCV002059502 pathogenic Hereditary spastic paraplegia 7 2021-09-08 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000627428 SCV002064526 pathogenic not provided 2018-04-17 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV000824802 SCV002105205 pathogenic Hereditary spastic paraplegia 2020-02-01 criteria provided, single submitter clinical testing
3billion RCV000461092 SCV002572690 pathogenic Hereditary spastic paraplegia 7 2022-09-01 criteria provided, single submitter clinical testing The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.015%). Frameshift variant is predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000411675 / PMID: 18563470 / 3billion dataset). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
CeGaT Center for Human Genetics Tuebingen RCV000627428 SCV004010530 pathogenic not provided 2023-05-01 criteria provided, single submitter clinical testing SPG7: PVS1, PM2, PM3
PreventionGenetics, part of Exact Sciences RCV003401491 SCV004118913 pathogenic SPG7-related condition 2023-07-27 criteria provided, single submitter clinical testing The SPG7 c.1053dupC variant is predicted to result in a frameshift and premature protein termination (p.Gly352Argfs*44). This variant has been reported in the homozygous and compound heterozygous state in patients with autosomal recessive hereditary spastic paraplegia (e.g., Tzoulis et al. 2008. PubMed ID: 18563470, designated 1047insC; Pfeffer et al. 2015. PubMed ID: 25681447). This variant is reported in 0.036% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-89598370-G-GC). Frameshift variants in SPG7 are expected to be pathogenic. This variant is interpreted as pathogenic.
Genomics England Pilot Project, Genomics England RCV000461092 SCV001760390 pathogenic Hereditary spastic paraplegia 7 no assertion criteria provided clinical testing
GeneReviews RCV000461092 SCV004034074 not provided Hereditary spastic paraplegia 7 no assertion provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.